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Purpose: Platelet inhibition is a key strategy in the management of atherothrombosis. However, 
the large variability in response to current strategies leads to the search for alternative inhibi-
tors. The antiplatelet effect of the inorganic salt sodium tungstate (Na
2
O
4
W), a protein tyrosine 
phosphatase 1B (PTP1B) inhibitor, has been investigated in this study.
Methods: Wild-type (WT) and PTP1B knockout (PTP1B-/-) mice were treated for 1 week with 
Na
2
O
4
W to study platelet function with the platelet function analyzer PFA-100, a cone-and-
plate analyzer, a flat perfusion chamber, and thrombus formation in vivo. Human blood aliquots 
were incubated with Na
2
O
4
W for 1 hour to measure platelet function using the PFA-100 and the 
annular perfusion chamber. Aggregometry and thromboelastometry were also performed.
Results: In WT mice, Na
2
O
4
W treatment prolonged closure times in the PFA-100 and decreased 
the surface covered (%SC) by platelets on collagen. Thrombi formed in a thrombosis mice model 
were smaller in animals treated with Na
2
O
4
W (4.6±0.7 mg vs 8.9±0.7 mg; P0.001). Results 
with Na
2
O
4
W were similar to those in untreated PTP1B-/- mice (5.0±0.3 mg). Treatment of 
the PTP1B-/- mice with Na
2
O
4
W modified only slightly this response. In human blood, a dose-
dependent effect was observed. At 200 μM, closure times in the PFA-100 were prolonged. 
On denuded vessels, %SC and thrombi formation (%T) decreased with Na
2
O
4
W. Neither the 
aggregating response nor the viscoelastic clot properties were affected.
Conclusion: Na
2
O
4
W decreases consistently the hemostatic capacity of platelets, inhibiting their 
adhesive and cohesive properties under flow conditions in mice and in human blood, resulting 
in smaller thrombi. Although Na
2
O
4
W may be acting on platelet PTP1B, other potential targets 
should not be disregarded.
Keywords: sodium tungstate, protein tyrosine phosphatase 1B, platelet adhesion, antiplatelet 
agents
Introduction
Atherothrombosis remains the leading cause of morbidity and mortality in Western 
society. Platelets play a key role in hemostasis, but they are also responsible for the 
pathologic thrombus formation underlying the clinical manifestations of acute athero-
thrombotic vascular disease.1 Therefore, modulation of platelet activation is a main 
goal for the development of pharmacological strategies to prevent the occurrence of 
cardiovascular accidents. Platelet activation occurs through multiple pathways and 
current agents do not interfere with all of them.
In patients suffering from acute coronary syndromes or undergoing percutane-
ous coronary intervention, oral antiplatelet treatment is routinely administered to 
inhibit platelet-mediated thrombus formation and the subsequent vessel occlusion. 
While currently available oral antiplatelet agents such as aspirin and P2Y12 adenos-
ine 5′-diphosphate (ADP) receptor antagonists reduce the incidence of ischemic 
events, the residual risk for morbidity and mortality remains substantially elevated.2,3 
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Interindividual response variability to aspirin and, especially, 
to clopidogrel makes it difficult to find the appropriate bal-
ance between the risk of thrombosis and bleeding in associa-
tion with the treatment with these compounds.4–7 Therefore, 
there is continuous search for new alternatives providing 
more rapid and consistent platelet inhibition.
Sodium tungstate (Na
2
O
4
W) has been demonstrated 
to be effective in normalizing blood glucose levels and in 
decreasing the body weight gain and adiposity in animal 
models of diabetes8 and obesity. Na
2
O
4
W has been shown to 
increase the expression of the uncoupling protein 1 (UCP1) 
and 3 (UCP3) genes,8,9 implicated in the control of adaptive 
thermogenesis, the production of reactive oxygen species 
by mitochondria, the regulation of ATP synthesis, and the 
regulation of fatty acid oxidation. Na
2
O
4
W was patented 
as an antiobesity agent. In three different phase I studies 
in healthy volunteers, Na
2
O
4
W demonstrated a very wide 
tolerance window for a 6-week period. In a phase II study 
in obese patients under treatment with Na
2
O
4
W for 6 weeks, 
the antiobesity effect was low although positive.10 Tungstate 
shares molecular similarities with vanadate (VO
4
3-), both 
being salts of trace transition metals in biological systems, 
with insulin-mimetic effects.11 Vanadate and Na
2
O
4
W are 
phosphate analogs and they act as protein tyrosine phos-
phatase (PTP) inhibitors. Because vanadate has been shown 
to inhibit PTP1B, it would be plausible to think that Na
2
O
4
W 
could also exhibit a similar effect.12 PTP1B plays a major 
role in the activation of platelets13 and is required for normal 
platelet thrombus formation in living mice.14 In this regard, 
we have indirect in vitro evidence of a potential effect of 
Na
2
O
4
W on platelet function.
The aim of the present study was to investigate the 
potential effect of Na
2
O
4
W as an antiplatelet agent using 
different approaches aimed to evaluate the adhesive and 
cohesive properties of platelets. Primary hemostasis was 
evaluated in wild-type (WT) and PTP1B knockout mice, 
after a week of treatment with Na
2
WO
4
 in drinking water. 
In vitro studies were also carried out in human blood samples 
treated with Na
2
O
4
W.
Materials and methods
experimental design
Studies were designed to evaluate the effect of Na
2
WO
4
 
on platelet function. WT and PTP1B knockout (PTP1B-/-) 
mice15,16 were treated for a week with Na
2
WO
4
 (2 g/L in 
drinking water). To analyze platelet function under flow 
conditions, four different approaches were applied: the plate-
let function analyzer PFA-100, the cone-and-plate analyzer 
(CPA), a small flat perfusion chamber, and the inferior vein 
cava (IVC) ligation model (an in vivo model that evaluates 
the pathophysiology of deep vein thrombosis in mice).
Studies on human blood were performed in vitro with 
either whole blood or platelet-rich plasma (PRP) incubated 
with Na
2
WO
4
. The effect of different concentrations of 
Na
2
WO
4
 (100 μM, 200 μM, and 400 μM, for 1 hour at 37°C) 
on platelet function was evaluated using the PFA-100 and the 
annular perfusion chamber. The concentration of 200 μM was 
then applied for aggregometry and thromboelastometry.
studies on mice
All the experiments were performed in 8-week-old male mice 
littermates, of a mixed C57BL/6J×129 background. Mice 
were housed under standard conditions of light (12-hour 
light/dark cycles) and temperature (21°C). Animals were fed 
ad libitum with standard chow diet (type A04 from Panlab, 
Barcelona, Spain) and received 2 g/L Na
2
O
4
W for a week. 
All animal procedures were approved by the Animal Ethics/
Research Committee of the University of Barcelona, and 
principles of laboratory animal care were followed.
Animals were anesthetized with an intraperitoneal injec-
tion of ketamine–xylazine, and intracardiac puncture was 
performed to obtain approximately 800 μL of blood antico-
agulated with 110 mM trisodium citrate (1:10, vol/vol).
hemostatic capacity in the PFa-100
The PFA-100 can be considered a substitute for the classic 
bleeding time test. The system monitors platelet interaction 
on membranes coated with collagen–ADP (Col–ADP) and 
collagen–epinephrine (Col–Epi).17 The system comprises a 
microprocessor-controlled instrument and a disposable test 
cartridge containing a biologically active membrane. The 
instrument aspirates a blood sample (citrated blood) under 
constant vacuum from the sample reservoir through a capil-
lary and a microscopic aperture cut into the membrane. The 
membrane is coated with Col–Epi or Col–ADP. The presence 
of these biochemical stimuli, as well as the high shear rates 
generated under the standardized flow conditions, result in 
platelet attachment, activation, and aggregation, slowly build-
ing a stable platelet plug at the aperture. The time required 
to obtain full occlusion of the aperture is reported as the 
“closure time,” which is expressed in seconds.
cPa testing
The CPA was used as previously described.18 The device tests 
platelet adhesion and aggregation in citrated whole blood under 
arterial flow conditions (1,800/second for 2 minutes). Blood is in 
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contact with the polystyrene surface of a well by using laminar 
flow. Three parameters were evaluated: the surface covered by 
platelets (expressed in percentage, %SC), the average size of 
the polystyrene-bound platelet clusters or platelet aggregates 
(AS, μm2), and the number of platelet groups (OB, n).
Experiments in flat perfusion devices
The interaction of mouse platelets with collagen-coated cov-
erslips (100 μg per coverslip) was explored in a low-volume 
flat perfusion device. Citrated blood samples were perfused 
for 5 minutes at a shear rate of 1,200/second adjusted with a 
peristaltic pump (Renal Systems, Minneapolis, MN, USA).
Perfused surfaces were fixed (2.5% glutaraldehyde in 
0.15 M phosphate-buffered saline [PBS], 4°C, 24 hours), 
stained with toluidine blue (0.02%), and platelet interactions 
evaluated by light microscopy. Morphometric analysis was 
performed using a computerized system (Image J), and plate-
let interactions were globally expressed as the percentage of 
the surface covered by platelets (%SC).
in vivo thrombosis model
IVC ligation model was used as previously described.19 
Briefly, mice (n=8 for each group) were anesthetized with 
a 2% mixture of isoflurane–oxygen and placed in a supine 
position. After laparotomy, intestines were exteriorized and 
sterile saline was applied during the whole procedure to pre-
vent drying. Posterior venous branches were cauterized and 
all visible side branches (usually one or two) were ligated. 
Then, gentle separation from aorta was performed and IVC 
was ligated using a 7-0 polypropylene suture immediately 
below the renal veins to obtain complete blood stasis. After 
surgery, peritoneum and skin were closed with a 6.0 mm-size 
monofilament suture. Mice were euthanized after 3 hours, 
and the vessel just below the renal veins and proximal to 
the confluence of the common iliac veins was excised. 
Mice showing any sign of tissue injury during surgery were 
excluded from further analysis.
studies with human blood
Blood sampling
Blood was drawn from healthy volunteers who had not 
ingested drugs affecting platelet function in the previous 
10 days. All donors gave their written informed consent to 
participate in the study. The study was performed in agree-
ment with the Declaration of Helsinki and was approved by 
the Ethical Committee of the Hospital Clinic (Barcelona). 
Blood was anticoagulated with 110 mM trisodium citrate 
(1:10, vol/vol) and incubated with different concentrations 
of Na
2
WO
4
 (0 μM, 100 μM, 200 μM, and 400 μM) for 
1 hour at 37°C.
experiments in annular perfusion devices
Aorta segments of enzymatically denuded New Zealand 
rabbits were mounted inverted on the central plastic rod 
of the perfusion chamber.20 Citrated blood samples were 
recirculated for 10 minutes at shear rates of 800/second 
and 1,200/second adjusted with a peristaltic pump (Renal 
Systems). Perfused surfaces were rinsed with 0.15 M PBS, 
fixed (2.5% glutaraldehyde in 0.15 M PBS, 4°C, 24 hours), 
dehydrated with a raising ethanol gradient, embedded in 
JB-4, thin sectioned for light microscopy, and stained with 
methylene blue. Platelet interactions were evaluated with 
light microscopy and a software21 that quantifies platelet 
coverage – expressed as percentage (%SC) – and calculates 
interactions higher than 5 μm (%T).
aggregation studies using turbidimetric techniques
PRP was obtained by centrifugation of whole blood (120 g, 
15 minutes). PRP aliquots were incubated with Na
2
O
4
W by 
gentle stirring in a conventional aggregometer (Aggrecorder 
PA 3210 aggregometer; Menarini Diagnostic, Firenze, Italy). 
Platelets were activated with arachidonic acid (AA, 1.6 mM), 
ADP (4 μM and 2 μM), collagen (Col, 5 μg/mL), and ristoce-
tin (R, 1 mg/mL) (10 minutes, 37°C) under stirring. Changes 
in turbidimetric patterns were registered and results expressed 
as percentage maximal aggregation.22
Thromboelastometry studies
Dynamic thrombelastography of whole-blood coagulation 
was explored using the EXTEM, INTEM, and FIBTEM 
tests in the rotational thromboelastometry analyzer (Penta-
pharmGmbH, Munich, Germany).23 EXTEM uses tissue 
factor as activator and measures changes in the extrinsic 
pathway of coagulation, fibrinogen and fibrin polymerization, 
and platelet function. In the FIBTEM test, platelet function 
is eliminated with cytochalasin D, obtaining a fibrin clot. 
The INTEM test uses ellagic acid to measure changes in the 
intrinsic pathway of coagulation.
Clotting time, clot formation time, clot amplitude after 
10 minutes (A10), maximum velocity (MaxV), and time to 
maximum clot formation velocity (MaxV-t) were evaluated. 
The clotting time and the clot formation time indicate the 
dynamics of clot formation. The clot amplitude gives infor-
mation about clot strength and stability, largely dependent 
on fibrinogen and platelets, and MaxV and MaxV-t express 
the clot formation velocity.
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statistics
Results are expressed as mean ± standard error of the mean 
(SEM). Statistical analysis was performed with raw data 
using Student’s t-tests for paired and unpaired samples. The 
results were considered significant at P0.05.
Results
effect of sodium tungstate on mouse 
platelets
Platelet function in the PFa-100
In WT mice (n=8), closure times were 148±17.4 seconds 
and 211±18 seconds when using the Col–ADP and Col–Epi 
cartridges, respectively. Closure times in the Col–Epi car-
tridges were already prolonged in untreated animals and 
no significant additional effect of Na
2
O
4
W was detected 
(227±10 seconds). In Col–ADP cartridges, Na
2
O
4
W 
treatment significantly prolonged the closure time up to 
272.8±12.4 seconds (P0.01) (Figure 1).
In PTP1B-/- mice (n=8), closure times in untreated 
animals were 292.9±4.5 seconds and 256±10 seconds when 
using the Col–ADP and Col–Epi cartridges, respectively. 
In Na
2
O
4
W-treated mice, closure times did not significantly 
differ either in the Col–ADP cartridge (258.6±13.3 seconds) 
or in the Col–Epi cartridge (196.6±61 seconds) groups 
(Figure 1).
Platelet interaction in the cPa
In WT animals (n=8), SC (%), AS (μm2), and OB (n) in the 
absence of Na
2
O
4
W were 1.40%±0.39%, 32.9±1.82 μm2, 
and 47.9±11.7, respectively. After treatment, both SC and 
OB increased significantly to 4.5%±1.4% and 783.1±229.4, 
respectively (P0.05); AS decreased significantly to 
22.2±0.8 μm2 (P0.05) (Figure 2). The increased SC may 
be due to the higher number of single platelets (OB) that are 
unable to aggregate among them in the presence of Na
2
O
4
W 
but that may adhere onto the plastic surface, probably through 
unspecific mechanisms.
In untreated PTP1B-/- mice (n=8), SC, AS, and OB were 
1.75%±0.79%, 32.1±2.8 μm2, and 100.1±25.28, respec-
tively. After treatment with Na
2
O
4
W, SC and AS decreased 
slightly to 0.64%±0.14% and 26.13±02.1 μm2 (P0.01), 
respectively, and OB increased moderately to 146.5±33.87 
(Figure 2).
Platelet interaction with collagen under flow 
conditions
The %SC on collagen-coated surfaces perfused for 5 minutes 
with blood from WT mice was 44.39%±3.43% (mean ± 
SEM, n=5). When adhesion studies were performed with 
the blood of Na
2
O
4
W-treated animals, %SC was reduced to 
30.72%±1.26%, this decrease being statistically significant 
(P0.01) (Figure 3).
With blood from PTP1B-/- mice, no changes were observed 
after Na
2
O
4
W treatment. The %SC was 13.86%±0.35% and 
16.23%±0.74% before and after treatment with Na
2
O
4
W, 
respectively (Figure 3).
in vivo thrombosis model
Because the previous experiments showed that Na
2
O
4
W 
decreases the hemostatic capacity of platelets, we wanted 
to explore the effect of this compound in vivo. Mice 
treated with Na
2
O
4
W showed decreased thrombi weights 
after 3 hours in the IVC stasis model (4.6±0.7 mg in 
treated mice vs 8.9±0.7 mg in nontreated mice; P0.001; 
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Figure 1 Mouse platelet function after na2O4W treatment.
Notes: cTs at the PFa-100 were measured using citrated blood samples. na2O4W treatment of WT mice (A) prolonged the cT in col–aDP cartridges, (B) being unchanged 
in col–epi cartridges. cT in PTP1B-/- mice were almost identical to those obtained in WT animals treated with W. Data are expressed as mean ± seM (n=8, *P0.01).
Abbreviations: col–aDP, collagen–adenosine 5′-diphosphate; col–epi, collagen–epinephrine; cT, closure time; KO, knockout mice; PFa-100, platelet function analyzer; 
PTP1B-/-, protein tyrosine phosphatase 1B knockout; seM, standard error of the mean; W, na2O4W; WT, wild type.
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Figure 2 effect of na2O4W on different parameters measured in a cone and plate analyzer.
Notes: W treatment of WT mice increased the surface covered by platelets (sc, %) and the number of objects (OB, n) adhered, though it decreased the average size of the 
aggregates (as, μm2). in PTP1B-/- mice, both sc and OB were lower and a slight decrease in the as was also detected in response to W. Data are expressed as mean ± seM 
(n=8, *P0.05 vs nontreated WT, #P0.01 vs nontreated PTP1B-/-).
Abbreviations: KO, knockout mice; PTP1B-/-, protein tyrosine phosphatase 1B knockout; seM, standard error of the mean; W, na2O4W; WT, wild type.
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Figure 3 Mouse platelet adhesion on collagen under flow conditions.
Notes: (A) Micrographs show groups of platelets adhered onto a collagen-rich surface perfused with citrated blood from untreated WT mice (WT) or treated with na2O4W 
(WT+W). (B) Bar diagram represents the corresponding surface covered by platelets (%) expressed as mean ± seM (n=5, *P0.01 vs untreated WT; #P0.001 untreated 
PTP1B-/- vs untreated WT).
Abbreviations: KO, knockout mice; seM, standard error of the mean; W, na2O4W; WT, wild type; PTP1B
-/-, protein tyrosine phosphatase 1B knockout.
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Figure 4). Moreover, we also studied thrombus formation in 
the PTP1B-/- mice and analyzed whether these differences 
could be potentiated by Na
2
O
4
W. PTP1B-/- mice showed 
smaller thrombi than WT mice (5.0±0.3 mg in nontreated 
PTP1B-/- mice vs 8.9±0.7 mg in nontreated WT mice; 
P0.001), reflecting a defect in platelet function in these 
mice, as previously described.14 Na
2
O
4
W reduced thrombi 
weight to a significantly greater extent in these animals 
(2.8±0.4 mg in treated PTP1B-/- mice vs 5.0±0.3 mg in 
nontreated PTP1B-/- mice; P0.01), indicating that the 
mechanisms by which Na
2
O
4
W affects hemostasis would be 
not only through PTP1B. Therefore, other potential targets 
should not be disregarded.
effect of sodium tungstate on human 
platelets
Platelet function in the PFa-100
Closure times in the absence of Na
2
O
4
W were 149.1±6.1 sec-
onds (mean ± SEM, n=10) and 99.9±4.3 seconds in Col–Epi 
and Col–ADP cartridges, respectively (Figure 5).
In the presence of 100 μM, 200 μM, and 400 μM of 
Na
2
O
4
W, closure times were prolonged in a concentra-
tion-dependent manner to 182.3±5.5 seconds (P0.01), 
203.6±17.9 seconds (P0.01), and 198.3±7.8 seconds 
(P0.001), respectively, in the Col–Epi cartridges 
(Figure 5). In the Col–ADP cartridges, only the highest 
concentration of Na
2
O
4
W used (400 μM) resulted in a 
significantly delayed closure time (175.7±36 seconds, 
P0.005) (Figure 5).
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Figure 4 iVc ligation model.
Notes: Bars represent weights (milligrams) of harvested iVc wet thrombi 3 hours 
after DVT induction, obtained from untreated WT mice (WT), WT mice treated 
with na2O4W (WT+W), untreated PTP1B-/- mice (KO), or PTP1B-/- mice treated 
with na2O4W (KO+W). eight mice for each group were assayed (*P0.05; 
**P0.01; ***P0.001; student’s t-test).
Abbreviations: DVT, deep vein thrombosis; iVc, inferior vein cava; KO, knockout 
mice; PTP1B-/-, protein tyrosine phosphatase 1B knockout; seM, standard error of 
the mean; W, na2O4W; WT, wild type.
Platelet interaction with subendothelial surfaces 
under flow conditions
Perfusion assays were carried out with denuded vessel seg-
ments at moderate shear rates. In the absence of Na
2
O
4
W, 
morphometric analysis of the surfaces perfused at 800/second 
showed that %SC in control samples after 10 minutes of per-
fusion was 33.0%±1.0% (mean ± SEM, n=9). In the presence 
of 100 μM (n=4), 200 μM (n=9), and 400 μM (n=4) Na
2
O
4
W, 
%SC was significantly reduced to 30.7%±3.9%, 18.0%±2.4% 
(P0.001), and 27.0%±2.7% (P0.05). Aggregates of 5 μm 
(%T) were found covering 56.3%±4.4% of the SC in the 
absence of Na
2
O
4
W, while on those surfaces perfused with 
blood samples preincubated with 100 μM, 200 μM, and 
400 μM of this compound, there was a significant decrease 
in the percentage of the surface covered by large thrombi, to 
38.1%±12.7%, 32.1%±4.0% (P0.005), and 38.2%±9.4%, 
respectively (Figure 5B). Representative micrographs are 
shown in Figure 6.
The concentration of 200 μM of Na
2
O
4
W was used to 
perform the remaining experiments with human blood. 
Using this concentration, similar results were obtained at a 
shear rate of 1,200/second (reductions of 63.8%±4.8% and 
67.4%±3.6% in the %SC and %T, both P0.05, respectively, 
were observed in the presence of Na
2
O
4
W).
Platelet aggregation using turbidimetric techniques
Samples of PRP before and after being incubated with 
200 μM Na
2
O
4
W for 1 hour were activated with AA, ADP 4, 
ADP 2, Col, and R for 5 minutes. Results expressed as per-
centage of maximal aggregation (mean ± SEM, n=10) were 
82.5%±3.3%, 86.4%±3.6%, 78.0%±8.1%, 91.5%±2.8%, and 
71.1%±6.8%, respectively. In the presence of Na
2
O
4
W, 
percentage of maximal aggregation was 81.2%±7.0%, 
82.8%±5.4%, 54.3%±9.0%, 84.7%±6.4%, and 72.7%±6.2%, 
respectively. Although results did not differ significantly, a 
decrease in the aggregating response to the lower concentra-
tion of ADP assayed was detected (P=0.06).
Thromboelastometric properties of blood clot
In the presence of 200 μM Na
2
O
4
W, no significant differ-
ences were observed in the parameters measured in the three 
different tests applied (Table 1).
Discussion
The majority of drugs developed as antiplatelet agents basi-
cally affect platelet membrane receptors and metabolic path-
ways and have a major impact on platelet function. Although 
most of them have shown clinical efficacy in reducing 
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Figure 5 Platelet interaction with subendothelial surfaces under flow conditions.
Notes: Bar diagrams show the effect of incubating citrated blood samples with different concentrations of na2O4W on (A) the closure times (seconds) in the PFa-100 device 
when using col–epi (black bars) and col–aDP (gray bars) cartridges and (B) the platelet adhesion on denuded vascular segments (perfused at 800/second for 10 minutes). 
surface coverage (sc; black bars); surface covered by thrombi ([T] with respect to the total sc; gray bars). Data are expressed as mean ± seM (*P0.01, **P0.001, 
#P0.005 vs the corresponding nontreated sample’s value).
Abbreviations: col–aDP, collagen–adenosine 5′-diphosphate; col–epi, collagen–epinephrine; PFa-100, platelet function analyzer; seM, standard error of the mean; 
W, na2O4W; WT, wild type.
???????
?????????
Figure 6 Micrographs showing platelet adhesion on subendothelial surfaces in the presence of na2O4W.
Notes: citrated blood samples, before (control) and after being incubated with 200 μM na2O4W (Tungstate), were perfused on denuded rabbit aorta segments at 800/
second, for 10 minutes. images are representative of nine different experiments.
morbidity and mortality in patients with atherothrombotic 
disease, these agents are associated with a residual risk of 
thrombotic events, risk of bleeding, and high variability in the 
patients’ responses. The use of a simple molecule targeting 
signaling proteins such as PTPs, which regulate partial aspects 
of platelet function, could lead to a more manageable effect 
on platelet function. Our present in vivo and in vitro studies 
demonstrate that Na
2
O
4
W significantly inhibits platelet inter-
action with subendothelial surfaces under flow conditions, 
decreasing the adhesive and cohesive properties of platelets 
without interfering with the thromboelastometric properties of 
blood clot. These differences resulted in smaller thrombi in a 
deep vein thrombosis mouse model induced by blood stasis.
Thrombotic complications attributed to platelets require 
prior formation of a mural thrombus. The thrombus or embo-
lized portions can be responsible for downstream ischemic 
complications. Several factors are known to participate in the 
regulation of thrombus formation. Platelet adhesion to the 
vessel wall increases with shear stress.24 Glycoprotein IIb-IIIa 
is expressed in an active conformation after platelets 
become exposed to damaged arterial surfaces under flow 
conditions.25,26 Thrombin generated through the activation 
of the coagulation system, and thromboxane A2 (TXA2) 
generated through arachidonic acid metabolism, are powerful 
activating agents, facilitating platelet deposition and growth 
of aggregates.27–29 In addition, platelets possess several recep-
tors for ADP on their membrane surface and contain ADP 
and other vasoactive substances in their storage granules, 
which are released during platelet secretion,29 a step of critical 
importance in the regulation of platelet responses.30
Inhibition of platelet aggregation can be achieved by 
either the blockade of membrane receptors or by interfering 
with intracellular pathways. Inhibition of arachidonic acid 
metabolism by aspirin and blockade of the ADP receptors 
by thienopyridines are currently the more widely used 
antiplatelet strategies. In fact, current standard treatment for 
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the prevention of thrombosis after percutaneous coronary 
intervention in acute coronary syndrome patients is dual 
antiplatelet therapy with aspirin and the thienopyridine 
clopidogrel.31–33 However, high platelet reactivity and 
genetic polymorphisms affect patient response to antiplatelet 
treatment.34–36 Although newly developed thienopyridine 
compounds, such as prasugrel, seem to be effective anti-
platelet agents, they exhibit increased associated risk of 
bleeding and higher acquisition cost compared with clopi-
dogrel. Thus, there is continuous search for newer agents 
with less variable antiplatelet activity and lower associated 
bleeding risk.
Na
2
O
4
W is a phosphatase inhibitor having antidi-
abetic properties,37,38 with an excellent therapeutic profile 
in both long- and short-term treatments.39,40 Administered 
orally, Na
2
O
4
W normalizes glycemia in mouse models of 
diabetes.40,41 It also increases the total amount and transloca-
tion of GLUT4 transporter in muscle42 and restores the glucose 
hepatic metabolism in streptozotocin-induced diabetic rats.11 
In streptozotocin-treated neonatal rats, Na
2
O
4
W adminis-
tration stimulates insulin secretion43 and regenerates β-cell 
population.41 Na
2
O
4
W also reduces weight gain and adiposity 
by increasing energy dissipation and fatty acid oxidation rate 
in an obese rat model.8 In a phase II study10 in obese patients 
treated with Na
2
O
4
W for 6 weeks, the antiobesity effect was 
positive although low, probably due to the short treatment 
duration and the lack of a hypocaloric diet used synergistically, 
among other limitations. Despite all the evidence generated, 
the precise molecular mechanisms of Na
2
O
4
W action are not 
yet defined. In the context of diabetes, a recent study in an 
animal model44 points to the effect of Na
2
O
4
W on different 
phosphatases, such as PTP1B and PP1, and also on G-proteins, 
all these being key elements in platelet function.
In our studies with Na
2
O
4
W-treated WT mice, hemostasis 
was significantly delayed, as evidenced by prolonged closure 
times at the PFA-100, using the COL–ADP cartridge, and 
lower rates of surface covered by platelets on perfused col-
lagen surfaces. The PFA-100 assay was designed for the 
screening of primary hemostasis in humans, and not in other 
animal species, and some differences between the results 
with mice and human blood could be expected. The in vivo 
model of thrombosis in mice showed a consistent inhibi-
tory effect of Na
2
O
4
W on thrombi formation. Interestingly, 
when blood samples were from PTP1B-/- mice, results were 
similar to those obtained with blood from WT mice in the 
presence of Na
2
O
4
W and no additional effect was observed 
when PTP1B-/- mice were treated. In experiments with 
human blood, a moderate and consistent effect decreasing 
both the adhesive and cohesive properties of platelets, when 
interacting with denuded vascular segments under flow con-
ditions, was observed in the presence of Na
2
O
4
W. Patterns 
of interaction were more similar to those reported with the 
ADP receptor inhibitors than with aspirin. It is interesting 
to mention that the effect of Na
2
O
4
W on hemostasis seems 
to be directed toward platelet function because no action 
on the coagulation system could be observed. The effect 
of Na
2
O
4
W on the hemostatic properties of platelets was 
detected only when applying flow techniques using whole 
blood. Although the effect seems restricted to platelets, 
an in vivo model showed a marked decrease in venous 
thrombus formation, indicating that Na
2
O
4
W acted as an 
antithrombotic drug. Indeed, previous studies45,46 have 
shown that the IVC stasis model requires a proper platelet 
function through interaction with endothelial cell-derived 
von Willebrand factor.
The effects of Na
2
O
4
W on the adhesive and cohesive 
properties of platelets could be related to PTP1B, as derived 
from results in the mouse model. In fact, results with blood 
from the PTP1B-/- mice are quite coincident with the results 
with blood from WT animals treated with Na
2
O
4
W, and 
Table 1 effect of tungstate on the viscoelastic properties of clots
ClotT CFT A10 (mm) MaxV (mm/min) MaxV-t (seconds)
eXTeM
control 55.5±10.5 95.5±10.5 53.0±2.0 13.5±1.5 113.0±4.0
Tungstate 60.0±5.0 84.5±3.5 54.0±1.0 14.5±0.5 115.0±18.0
inTeM
control 168.0±23.0 79.0±11.0 52.0±3.0 16.0±2.0 189.0±29.0
Tungstate 166.0±15.0 75.0±2.0 54.5±1.5 17.0±0.0 191.5±29.0
FiBTeM
control 54.5±6.5 na 11.0±1.0 10.5±2.5 58.0±6.0
Tungstate 56.5±0.5 na 12.0±0.0 12.5±1.5 58.5±0.5
Notes: clotT, cFT, a10, MaxV, and MaxV-t were evaluated. Data are expressed as mean ± seM (n=4). 
Abbreviations: clotT, clotting time; cFT, clot formation time; a10, clot amplitude after 10 minutes; MaxV, maximum velocity; MaxV-t, time to maximum clot formation 
velocity; na, not applicable; seM, standard error of the mean.
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treatment of PTP1B-/- mice with Na
2
O
4
W did not modify 
this response. PTP1B is a tyrosine phosphatase that regulates 
platelet functions that are dependent on outside–in αIIbβ3 
signaling,14 such as platelet spreading on fibrinogen and 
thrombus formation under flow conditions, by activation 
of c-Src, although it seems that it is not required for the 
agonist-induced activation of αIIbβ3.14 Despite this evidence, 
Na
2
O
4
W may be acting on other signaling mechanisms, which 
should be further explored.
Na
2
O
4
W is a compound with a reasonably delimited 
pharmacotoxicologic profile. It has satisfactorily passed 
three phase I clinical trials involving healthy volunteers 
without clinical, laboratory, or electrographic findings sug-
gesting toxicity.10 Na
2
O
4
W has been shown to be effective 
in both normalizing blood glucose levels and decreasing 
the body weight gain and adiposity. Through the present 
study, we have generated evidence for the first time dem-
onstrating the effect of Na
2
O
4
W modulating the adhesive 
and cohesive functions of platelets. Considering that the 
socioeconomic burden of atherothrombosis is still increasing 
in our society and that the current antiplatelet treatments are 
associated with thrombotic and/or bleeding risks, Na
2
O
4
W 
offers a potential antiplatelet strategy that should be further 
explored.
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